Prostate cancer is not a single disease. While the vast majority of cases are one type, acinar adenocarcinoma, there are several other forms that behave differently and require different treatment approaches. The five main types are acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (urothelial) carcinoma, small cell carcinoma, and prostate sarcoma. Understanding which type you’re dealing with matters because some grow slowly and respond well to standard treatments, while others are aggressive and need entirely different strategies.
Acinar Adenocarcinoma
This is the type almost everyone means when they say “prostate cancer.” Acinar adenocarcinoma develops in the small, round glands that produce prostatic fluid. It accounts for the overwhelming majority of prostate cancer diagnoses, with rare subtypes collectively making up less than half a percent of all cases in a large analysis of over 827,000 patients.
Acinar adenocarcinoma is the type detected through PSA screening and diagnosed via standard biopsy. It’s also the type that the Gleason grading system was designed to evaluate. Growth rates vary widely. Some acinar tumors are so slow-growing that active surveillance (monitoring without immediate treatment) is appropriate, while others are aggressive enough to require surgery, radiation, or hormone therapy. The behavior of acinar adenocarcinoma depends heavily on its grade and stage at diagnosis, which is why it’s classified on a spectrum rather than treated as one uniform disease.
Ductal Adenocarcinoma
Ductal adenocarcinoma is the most common of the non-acinar subtypes, though it’s still rare, appearing in roughly 0.5% to 6% of prostate cancer cases depending on how strictly pathologists define it. In a large database study, ductal carcinoma accounted for about 0.18% of all prostate cancers when identified as the dominant type.
Where acinar cancer grows in the small round glands, ductal adenocarcinoma forms in the larger ducts of the prostate. Under a microscope, the cells look distinctly different: they’re tall, layered on top of each other, and arranged in finger-like projections or sieve-like patterns. Most ductal tumors start in the outer zone of the prostate and extend inward toward the urethra.
This type is more aggressive than typical acinar adenocarcinoma. At the time of surgery, ductal cancers are more likely to have spread beyond the prostate capsule, invaded the seminal vesicles, or entered blood vessels. Because of this aggressive behavior, active surveillance is generally not recommended. If ductal features show up on a biopsy, treatment is usually pursued promptly.
Transitional Cell (Urothelial) Carcinoma
Transitional cell carcinoma, also called urothelial carcinoma, originates not from the prostate’s glandular tissue but from the lining cells found where the urinary tract passes through the prostate. These are the same type of cells that line the bladder, which is why this cancer sometimes develops as a primary bladder cancer that spreads into the prostate. When it starts in the prostate itself, it arises from the lining of the prostatic urethra or the ducts just beneath it.
The symptoms of transitional cell carcinoma feel different from typical prostate cancer. Rather than being caught on a routine PSA test, this type tends to cause noticeable urinary problems: blood in the urine, difficulty urinating, frequent urination, and pain during urination. These symptoms often mimic an enlarged prostate, which can delay diagnosis. PSA levels may not be elevated, so this cancer can be missed by standard prostate screening. Urine cytology, a test that looks for abnormal cells shed into the urine, is more useful for detection. Transitional cell carcinoma of the prostate carries a poor prognosis overall, partly because it is often diagnosed at a more advanced stage.
Small Cell Carcinoma
Small cell carcinoma of the prostate is a neuroendocrine cancer, meaning the tumor cells share features with nerve and hormone-producing cells rather than the glandular cells where most prostate cancers begin. It is rare, representing about 0.12% of prostate cancers in large population studies, but it is by far the most dangerous type.
One of the biggest challenges with small cell prostate cancer is that it doesn’t play by the usual rules. PSA levels typically don’t reflect how much disease is present, so standard screening misses it. Diagnosis relies on biopsy, where pathologists look for specific markers on the tumor cells. At least one of these markers is found in about 90% of small cell prostate cancer cases.
Standard hormone therapy, the backbone of treatment for most advanced prostate cancers, has limited effectiveness against small cell tumors because these cells don’t depend on testosterone to grow. Instead, treatment borrows from the playbook used for small cell lung cancer, which behaves similarly at the molecular level. Platinum-based chemotherapy combinations produce initial response rates of 50% to 60%, though the cancer often becomes resistant over time. Immunotherapy drugs are sometimes added, particularly for pure small cell tumors. Even so, hormone therapy is often still included alongside chemotherapy because many tumors contain a mix of small cell and conventional prostate cancer cells.
Small cell carcinoma can arise on its own, but it also develops in some men after prolonged hormone therapy for conventional prostate cancer. The cancer essentially adapts, transforming from a hormone-dependent type into a neuroendocrine type that no longer needs testosterone.
Prostate Sarcoma
Sarcomas are cancers of connective tissue, including muscle, fat, and fibrous tissue. Prostate sarcomas don’t develop from the glandular cells where adenocarcinomas begin. Instead, they grow from the structural tissue that holds the prostate together. They are extremely rare.
The median age at diagnosis is 63, though the range is broad, with some cases diagnosed in much younger men. In a study of 125 prostate sarcoma patients, the most common subtype was leiomyosarcoma (a cancer of smooth muscle tissue), accounting for 36% of cases. Rhabdomyosarcoma, which originates from skeletal muscle cells, made up 14%. Stromal sarcoma represented 12%. The remaining cases were split among more than a dozen other subtypes, each affecting only a handful of patients.
Because prostate sarcomas don’t arise from glandular tissue, they don’t respond to the hormone therapies or PSA-guided approaches used for adenocarcinoma. Treatment typically involves surgery and may include chemotherapy regimens designed for sarcomas elsewhere in the body. The rarity of these tumors means there’s no single standardized treatment pathway, and care is often guided by sarcoma specialists rather than urologists alone.
Why the Type Matters
If you or someone you know has been diagnosed with prostate cancer, the histological type on the pathology report is one of the most important details. A man with a low-grade acinar adenocarcinoma may safely monitor his cancer for years without treatment. A man with ductal adenocarcinoma needs prompt intervention. A man with small cell carcinoma needs a completely different treatment approach that most general oncologists wouldn’t use for prostate cancer.
The good news is that the vast majority of prostate cancer diagnoses are acinar adenocarcinoma, the type with the most treatment options and the most research behind it. The rare types collectively account for well under 1% of all cases. But if a pathology report mentions any of the less common types, it’s worth understanding what that means for prognosis and treatment, because the standard prostate cancer conversation may not fully apply.